GSK-3β targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3β inactivation correlates with Cdc25A overproduction in human cancers

被引:138
作者
Kang, Tiebang [1 ,2 ]
Wei, Yongkun [4 ]
Honaker, Yuchi [2 ]
Yamaguchi, Hiroshi [5 ]
Appella, Ettore [5 ]
Hung, Mien-Chie [4 ]
Piwnica-Worms, Helen [1 ,2 ,3 ]
机构
[1] Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA
[4] Univ Texas Houston, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA
[5] NCI, Natl Inst Hlth, Cell Biol Lab, Bethesda, MD 20892 USA
关键词
D O I
10.1016/j.ccr.2007.12.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Cdc25A phosphatase positively regulates cell-cycle transitions, is degraded by the proteosome throughout interphase and in response to stress, and is overproduced in human cancers. The kinases targeting Cdc25A for proteolysis during early cell-cycle phases have not been identified, and mechanistic insight into the cause of Cdc25A overproduction in human cancers is lacking. Here, we demonstrate that glycogen synthase kinase-3 beta (GSK-3 beta) phosphorylates Cdc25A to promote its proteolysis in early cell-cycle phases. Phosphorylation by GSK-3 beta requires priming of Cdc25A, and this can be catalyzed by polo-like kinase 3 (PIk-3). Importantly, a strong correlation between Cdc25A overproduction and GSK-3 beta inactivation was observed in human tumor tissues, indicating that GSK-3 beta inactivation may account for Cdc25A overproduction in a subset of human tumors.
引用
收藏
页码:36 / 47
页数:12
相关论文
共 64 条
[1]   Chk1 and Chk2 kinases in checkpoint control and cancer [J].
Bartek, J ;
Lukas, J .
CANCER CELL, 2003, 3 (05) :421-429
[2]   Pathways governing G1/S transition and their response to DNA damage [J].
Bartek, J ;
Lukas, J .
FEBS LETTERS, 2001, 490 (03) :117-122
[3]   Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation [J].
Bernardi, R ;
Liebermann, DA ;
Hoffman, B .
ONCOGENE, 2000, 19 (20) :2447-2454
[4]  
Blomberg I, 1999, MOL CELL BIOL, V19, P6183
[5]   The when and wheres of CDC25 phosphatases [J].
Boutros, R ;
Dozier, C ;
Ducommun, B .
CURRENT OPINION IN CELL BIOLOGY, 2006, 18 (02) :185-191
[6]  
Broggini M, 2000, ANTICANCER RES, V20, P4835
[7]  
Bunch RT, 1996, CLIN CANCER RES, V2, P791
[8]  
Busby EC, 2000, CANCER RES, V60, P2108
[9]   Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis [J].
Busino, L ;
Chiesa, M ;
Draetta, GF ;
Donzelli, M .
ONCOGENE, 2004, 23 (11) :2050-2056
[10]   Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage [J].
Busino, L ;
Donzelli, M ;
Chiesa, M ;
Guardavaccaro, D ;
Ganoth, D ;
Dorrello, NV ;
Hershko, A ;
Pagano, M ;
Draetta, GF .
NATURE, 2003, 426 (6962) :87-91